Drug Profile
Budesonide aerosolised - Pearl Therapeutics
Alternative Names: BD-MDI; BUD-MDI; Budesonide inhalation aerosol; PT-008Latest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator Pearl Therapeutics
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 11 Dec 2018 AstraZeneca plans a phase I trial in Volunteers in United Kingdom , (NCT03772223)
- 30 Sep 2016 Discontinued - Phase-II for Asthma in USA (Inhalation)
- 30 Sep 2016 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA (Inhalation)